A novel continuous powder aerosolizer (CPA) for inhalative administration of highly concentrated recombinant surfactant protein-C (rSP-C) surfactant to preterm neonates

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 26, Issue 6, 2013, Pages 370-379

  Pohlmann, G ^a   Iwatschenko, P ^b   Koch, W ^a   Windt, H ^a   Rast, M ^c   De Abreu, M Gama ^d   Taut, F J H ^e   De Muynck, C ^c  

^a FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

^b MTF MediTech Franken GmbH   (Germany)

^c Nycomed A Takeda Company   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e Takeda Pharmaceuticals International GmbH   (Switzerland)

Author keywords

Aerosolization; Dispersion; Drug delivery; Infant respiratory distress syndrome; Inhalation; Powder; Preterm neonate; Surfactant

Indexed keywords

LUNG SURFACTANT; LUSUPULTIDE;

AEROSOL; ARTICLE; CONTINUOUS POWDER AEROSOLIZER; DRUG DELIVERY DEVICE; DRY POWDER INHALER; HUMAN; HUMIDIFIER; LASER DIFFRACTION; LUNG FUNCTION; MEASUREMENT; NEBULIZATION; PARTICLE SIZE; PREMATURITY;

ADMINISTRATION, INHALATION; AEROSOLS; CHEMISTRY, PHARMACEUTICAL; EQUIPMENT DESIGN; HUMANS; HUMIDITY; INFANT, NEWBORN; INFANT, PREMATURE; MATERIALS TESTING; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; POWDERS; PULMONARY SURFACTANT-ASSOCIATED PROTEIN C; PULMONARY SURFACTANTS; RECOMBINANT PROTEINS; RESPIRATORY DISTRESS SYNDROME, NEWBORN;

EID: 84881523021     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2012.0996     Document Type: Article

References (26)

1. Shah S: Exogenous surfactant: intubated present, nebulized future? World J Pediatr. 2011;7:11-15.
2. Jorch G, Hartl H, Roth B, Kribs A, Gortner L, Schaible T, Hennecke H, and Poets C: Surfactant aerosol treatment of respiratory distress syndrome in spontaneously breathing premature infants [Letter]. Pediatr Pulmonol. 1997;24:222-224. (Pubitemid 27431233)
3. Pillow JJ, and Minocchieri S: Innovation in surfactant therapy II: Surfactant administration by aerosolization. Neonatology. 2012;101:337-344.
4. Shangle CE, Haas RH, Vaida F, Rich WD, and Finer NN: Effects of endotracheal intubation and surfactant on a-channel neonatal electroencephalogram. J Pediatr. 2012;161:252-257.
5. Morley CJ, Davis PG, Doyle LW, Brion LP, Hascoet JM, and Carlin JB; COIN Trial Investigators: Nasal CPAP or intubation at birth for very preterm infants. N Engl J Med. 2008;358:700-708. (Pubitemid 351240749)
6. Mazela J, Merritt TA, and Finer NN: Aerosolized surfactants. Curr Opin Pediatr. 2007;19:155-162. (Pubitemid 46668067)
7. Finer NN, Merritt TA, Bernstein G, Job L, Mazela J, and Segal R: An open label, pilot study of Aerosurf combined with nCPAP to prevent RDS in preterm neonates. J Aerosol Med Pulm Drug Deliv. 2010;23:303-309.
8. Hinds WC: Aerosol Technology, 2nd edition. John Wiley & Sons, New York; 1999.
9. Crowder M, and Donavan MJ: Science and technology of dry powder inhalers. In: HDC Smyth, and JA Hickey, (eds). Advances in Delivery Science and Technology: Controlled Pulmonary Drug Delivery. Springer, New York; pp. 203-222, 2011.
10. Schmalisch G, Wilitzki S, and Wauer GG: Differences in tidal breathing between infants with chronic lung diseases and healthy controls. BMC Pediatrics. 2005;5:36.
11. Fink JB: Aerosol delivery to ventilated infant and pediatric patients. Respir Care. 2004;49:653-665.
12. Sweet HG, Carnielli V, Greisen G, Hallman M, Ozek E, Plavka R, Saugstad OD, Simeoni U, Speer CP, and Halliday HL; European Association of Perinatal Medicine: European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants-2010 update. Neonatology. 2010;97:402-417.
13. Lewis JF, Ikegami M, Jobe AH, and Tabor B: Aerosolized surfactant treatment of preterm lambs. J Appl Physiol. 1991;70:869-876.
14. Rahmel DK, Pohlmann G, Iwatschenko P, Volland J, Liebisch S, Kock H, Mecklenburg L, Maurer C, Kemkowski J, and Taut FJH: The non-intubated, spontaneously breathing, continuous positive airway pressure (CPAP) ventilated preterm lamb: a unique animal model. Reprod Toxicol. 2012;34;204-215.
15. Köhler E, Jilg G, Avenarius S, and Jorch G: Lung deposition after inhalation with various nebulisers in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2008;93:F275-F279. (Pubitemid 352039397)
16. Broday DM, and Georgopoulos PG: Growth and deposition of hygroscopic particulate matter in the human lungs. Aerosol Sci Technol. 2001;34:144-159. (Pubitemid 32063231)
17. Iwatschenko P, Pohlmann G, Windt H, Koch W, and Kist M: Improved apparatus for the aerosolization of large volumes of dry powder. 2010; WO 2010/122103 A1.
18. Pohlmann G, Windt H, Nolte O, and Koch W: Device for dosing and dry nebulization. 2006; WO 2006/108558 A1.
19. Rahmel D, Taut F, De-Muynck C, Rast M, Iwatschenko P, Pohlmann G, Koch W, and Windt H: Humidified particles comprising a therapeutically active substance. 2012; WO 2012/025496 A1.
20. Iwatschenko P, Pohlmann G, Rahmel D, Taut F, De Muynck C, Koch W, and Windt H: Device and system for delivery of an aerosol to a patient on ventilatory support. 2012; WO 2012/020004 A1.
21. Butani VK, and Benitz WE: Pulmonary function and graphics. In: JP Goldsmith, and EH Karotkin, (eds). Assisted Ventilation of the Neonate, 5th ed. Elsevier, Philadelphia, PA; pp. 306-320, 2011.
22. Zaru M, Mourtas S, Klepetsanis P, Fadda AM, and Antimisiaris SG: Liposomes for drug delivery to the lungs by nebulization. Eur J Pharm Biopharm. 2007;67:655-666. (Pubitemid 47576612)
23. Schreier H, McNicol KJ, Ausborn M, Soucy DM, Derendorf H, Stecenko AA, Gonzalez-Rothi RJ: Pulmonary delivery of amikacin liposomes and acute liposome toxicity in the sheep. Int J Pharm. 1992;87:183-193.
24. Li Z, Zhang Y, Wurtz W, Lee JK, Malinin VS, Durwas-Krishnan S, Meers P, and Perkins WR: Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size. J Aerosol Med Pulm Drug Deliv. 2008;21:245-253.
25. Pohlmann G, Iwatschenko P, Koch W, Windt H, Rast M, Taut F, and De-Muynck C: Continuous powder aerosolization (CPA): a new device to administer inhalable particle formulations in high concentrations. AAPS Annual Meeting and Exposition, Chicago, IL, October 14-18, 2012; M1103.
26. Dolovich MB, and Dhand R: Aerosol drug delivery: developments in device design and clinical use. Lancet. 2011;377: 1032-1045.